TY  - JOUR
A1  - Aupperle-Lellbach, Heike
A1  - Heidrich, Daniela
A1  - Kehl, Alexandra
A1  - Conrad, David
A1  - Brockmann, Maria
A1  - Törner, Katrin
A1  - Beitzinger, Christoph
A1  - Müller, Tobias
T1  - KITLG copy number germline variations in schnauzer breeds and their relevance in digital squamous cell carcinoma in black giant schnauzers
JF  - Veterinary Sciences
N2  - Copy number variations (CNVs) of the KITLG gene seem to be involved in the oncogenesis of digital squamous cell carcinoma (dSCC). The aims of this study were (1) to investigate KITLG CNV in giant (GS), standard (SS), and miniature (MS) schnauzers and (2) to compare KITLG CNV between black GS with and without dSCC. Blood samples from black GS (22 with and 17 without dSCC), black SS (18 with and 4 without dSSC; 5 unknown), and 50 MS (unknown dSSC status and coat colour) were analysed by digital droplet PCR. The results are that (1) most dogs had a copy number (CN) value > 4 (range 2.5–7.6) with no significant differences between GS, SS, and MS, and (2) the CN value in black GS with dSCC was significantly higher than in those without dSCC (p = 0.02). CN values > 5.8 indicate a significantly increased risk for dSCC, while CN values < 4.7 suggest a reduced risk for dSCC (grey area: 4.7–5.8). Diagnostic testing for KITLG CNV may sensitise owners to the individual risk of their black GS for dSCC. Further studies should investigate the relevance of KITLG CNV in SS and the protective effects in MS, who rarely suffer from dSCC.
KW  - tumour
KW  - toe
KW  - miniature schnauzer
KW  - standard schnauzer
KW  - CNV
KW  - ddPCR
KW  - breed predisposition
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-303913
SN  - 2306-7381
VL  - 10
IS  - 2
ER  - 
TY  - JOUR
A1  - Metzenmacher, Martin
A1  - Váraljai, Renáta
A1  - Hegedüs, Balazs
A1  - Cima, Igor
A1  - Forster, Jan
A1  - Schramm, Alexander
A1  - Scheffler, Björn
A1  - Horn, Peter A.
A1  - Klein, Christoph A.
A1  - Szarvas, Tibor
A1  - Reis, Hennig
A1  - Bielefeld, Nicola
A1  - Roesch, Alexander
A1  - Aigner, Clemens
A1  - Kunzmann, Volker
A1  - Wiesweg, Marcel
A1  - Siveke, Jens T.
A1  - Schuler, Martin
A1  - Lueong, Smiths S.
T1  - Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer
JF  - Cancers
N2  - Early detection of cancer holds high promise for reducing cancer-related mortality. Detection of circulating tumor-specific nucleic acids holds promise, but sensitivity and specificity issues remain with current technology. We studied cell-free RNA (cfRNA) in patients with non-small cell lung cancer (NSCLC; n = 56 stage IV, n = 39 stages I-III), pancreatic cancer (PDAC, n = 20 stage III), malignant melanoma (MM, n = 12 stage III-IV), urothelial bladder cancer (UBC, n = 22 stage II and IV), and 65 healthy controls by means of next generation sequencing (NGS) and real-time droplet digital PCR (RT-ddPCR). We identified 192 overlapping upregulated transcripts in NSCLC and PDAC by NGS, more than 90% of which were noncoding. Previously reported transcripts (e.g., HOTAIRM1) were identified. Plasma cfRNA transcript levels of POU6F2-AS2 discriminated NSCLC from healthy donors (AUC = 0.82 and 0.76 for stages IV and I–III, respectively) and significantly associated (p = 0.017) with the established tumor marker Cyfra 21-1. cfRNA yield and POU6F2-AS transcript abundance discriminated PDAC patients from healthy donors (AUC = 1.0). POU6F2-AS2 transcript was significantly higher in MM (p = 0.044). In summary, our findings support further validation of cfRNA detection by RT-ddPCR as a biomarker for early detection of solid cancers.
KW  - liquid biopsy
KW  - cfRNA
KW  - cancer
KW  - ddPCR
KW  - NGS
KW  - POU6F2-AS2
KW  - early detection
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200553
SN  - 2072-6694
VL  - 12
IS  - 2
ER  -